Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Papillomavirus Infections 1

Interventions

Cisplatin 53Paclitaxel 27Carboplatin 22Brachytherapy 18Radiotherapy 17human papillomavirus vaccine, L1 type 16, 18 12Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Gemcitabine 12Topotecan 8Vaccines, Synthetic 7Platinum 7Papillomavirus Vaccines 7Radiation 6Bevacizumab 61,2-diaminocyclohexaneplatinum II citrate 6Neoadjuvant Therapy 5Chemotherapy, Adjuvant 5pembrolizumab 4Vinorelbine 4Radiotherapy, Intensity-Modulated 4Pemetrexed 4Drug Therapy 4Taxes 3Surgical Procedures, Operative 3Ondansetron 3Irinotecan 3Dexamethasone 3Chemoradiotherapy 3tisotumab vedotin 2specific substance maruyama 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Uterine Cervical Neoplasms × Chorionic Villi Sampling × Clear all
NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

GlaxoSmithKline

Phase 3 Completed
525 enrolled 24 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡